Recent studies showing acid ceramidase (AC) to be upregulated in melanoma, lung and prostate cancers have made the enzyme a desired target for novel synthetic inhibitor compounds. In Angewandte Chemie, scientists with the Univ. of California, Irvine School of Medicine and the Italian Institute of Technology describe the very first class of AC inhibitors that may aid in the efficacy of chemotherapies.
U.S. government health regulators on Thursday approved the first hard-to-abuse version of the painkiller hydrocodone, offering an alternative to a similar medication that has been widely criticized for lacking such safeguards. The FDA approved Purdue Pharma's Hysingla ER for patients with severe, round-the-clock pain that cannot be managed with other treatments.
The government proposed new rules Wednesday to make it easier for doctors and patients to learn if clinical trials of treatments worked or not. Thousands of Americans participate in clinical trials every year, testing new treatments, comparing old ones or helping to uncover general knowledge about health. Many of the studies are reported in scientific journals and trumpeted in the news.
A major challenge faced by the pharmaceutical industry has been how to rationally design and select protein molecules to create effective biologic drug therapies while reducing unintended side effects—a challenge that has largely been addressed through costly guess–and–check experiments. Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard Univ. offer a new approach.
A coalition of companies and aid groups announced plans Tuesday to test experimental drugs and collect blood plasma from Ebola survivors to treat new victims of the disease in West Africa. Plasma from survivors contains antibodies, substances the immune system makes to fight the virus.
Scientists at The Scripps Research Institute have identified weak spots on the surface of Ebola virus that are targeted by the antibodies in ZMapp, the experimental drug cocktail administered to several patients during the recent Ebola outbreak. The study provides a revealing 3-D picture of how the ZMapp antibodies bind to Ebola virus.
Small pieces of synthetic RNA trigger a RNA interference (RNAi) response that holds great therapeutic potential to treat a number of diseases, especially cancer and pandemic viruses. The problem is delivery: It’s extremely difficult to get RNAi drugs inside the cells in which they are needed.
Millions of people with stents that prop open clogged heart arteries may need anti-clotting drugs much longer than the one year doctors recommend now. A large study found that continuing for another 18 months lowers the risk of heart attacks, clots and other problems. Even quitting after 30 months made a heart attack more likely, raising a question of when it's ever safe to stop.
The editors of R&D Magazine have announced the opening of the 2015 R&D 100 Awards entry process. The R&D 100 Awards have a 50 plus year history of awarding the 100 most technologically significant products of the year. Past winners have included sophisticated testing equipment, innovative new materials, chemistry breakthroughs, biomedical products, consumer items, high-energy physics and more.
A trawl through a library of more than 50,000 small molecules has identified a potential candidate to inhibit the spread of cancer cells throughout the body. Reported in Nature Communications, the molecule targets a mechanism of tumor development that had previously been considered “undruggable” and could open the door to further promising new candidates.
Nanomedicine is offering patients a growing arsenal of therapeutic drugs for a variety of diseases, but often at a cost of thousands of dollars a month. Generics could substantially reduce the price tag for patients—if only there were a well-defined way to make and regulate them. An article in Chemical & Engineering News (C&EN) details the challenges on the road to generic nanodrugs.
Scientists have discovered gene mutations that give people naturally lower cholesterol levels and cut their risk of heart disease in half. That discovery may have a big implication: A blockbuster drug that mimics these mutations has long been sold without evidence that it cuts the chance of heart disease. Results of a large study that looked for that evidence will be revealed on Monday.
Use of “antibiograms” in skilled nursing facilities could improve antibiotic effectiveness and help address problems with antibiotic resistance. Antibiograms are tools that aid health care practitioners in prescribing antibiotics in local populations. They are based on information from microbiology laboratory tests and provide information on how likely a certain antibiotic is to effectively treat a particular infection.
Chemists at The Scripps Research Institute and the Shanghai Institute of Organic Chemistry have described a method for creating and modifying organic compounds that overcomes a major limitation of previous methods. The advance opens up a large number of novel chemical structures for synthesis and evaluation, for example, as candidate pharmaceuticals.
A potentially breathable, respiratory vaccine in development has been shown to provide long-term protection for non-human primates against the deadly Ebola virus. Results from a recent pre-clinical study represent the only proof to date that a single dose of a non-injectable vaccine platform for Ebola is long lasting, which could have significant global implications in controlling future outbreaks.
People with muscular dystrophy could one day assess the effectiveness of their medication with the help of a smartphone-linked device, a new study in mice suggests. The study used a new method to process ultrasound imaging information that could lead to hand-held instruments that provide fast, convenient medical information.
Researchers report in Nature that they have made a breakthrough in understanding how a powerful antibiotic agent is made in nature. Their discovery solves a decades-old mystery, and opens up new avenues of research into thousands of similar molecules, many of which are likely to be medically useful.
In early drug discovery, you need a starting point. In a new research paper published in PLOS-Neglected Tropical Diseases, a team of researchers present hundreds of such starting points for potentially treating Human African trypanosomiasis, or sleeping sickness, a deadly disease that affects thousands of people annually.
Houston Methodist Research Institute scientists will receive about $1.25 million from the Center for the Advancement of Science in Space to develop an implantable, nanochannel device that delivers therapeutic drugs at a rate guided by remote control. The device's effectiveness will be tested aboard the International Space Station and on Earth's surface.
A group of scientists in Florida have combined medicine and advanced nanotechnological engineering to create a smarter, more targeted therapy that could overcome the most lethal gynecologic cancer. The technology involves combining Taxol, a chemotherapy drug, with magneto-electric nanoparticles that can penetrate the blood-brain barrier.
New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side effects that kill at least 100,000 patients a year, according to Nature.
In a design that mimics a hard-to-duplicate texture of starfish shells, Univ. of Michigan engineers have made rounded crystals that have no facets. The team calls the crystals "nanolobes". The nanolobes' shape and the way they're made have promising applications. The geometry could potentially be useful to guide light in advanced LEDs, solar cells and non-reflective surfaces.
European Union nations are working to reach 1 billion euros ($1.27 billion) in aid by the end of the week to fight Ebola in West Africa and are seeking a common approach to the crisis.EU foreign ministers began a week of talks Monday so their 28 leaders can agree by Friday on better measures to fight Ebola, anything from financial aid to common repatriation procedures, more Ebola treatment facilities and better training for health workers.
Scientists have used computer simulations to show how bacteria are able to destroy antibiotics, a breakthrough which will help develop drugs which can effectively tackle infections in the future. Researchers at the Univ. of Bristol focused on the role of enzymes in the bacteria, which split the structure of the antibiotic and stop it working, making the bacteria resistant.
The new Urban Dynamics Institute at Oak Ridge National Laboratory is working with the Bill & Melinda Gates Foundation to aid polio vaccination efforts in developing countries. Teams at the institute will apply big data analysis to population dynamics in Nigeria, allowing polio vaccination crews to better estimate the amount of vaccine needed and to target areas of priority, saving time and money in eradicating the disease.